In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy.

circulating tumor cells in vivo detection non-metastatic prostate cancer radiotherapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
03 Jul 2019
Historique:
received: 12 05 2019
revised: 20 06 2019
accepted: 28 06 2019
entrez: 7 7 2019
pubmed: 7 7 2019
medline: 7 7 2019
Statut: epublish

Résumé

High-risk non-metastatic prostate cancer (PCa) has the potential to progress into lethal disease. Treatment options are manifold but, given a lack of surrogate biomarkers, it remains unclear which treatment offers the best results. Several studies have reported circulating tumor cells (CTCs) to be a prognostic biomarker in metastatic PCa. However, few reports on CTCs in high-risk non-metastatic PCa are available. Herein, we evaluated CTC detection in high-risk non-metastatic PCa patients using the in vivo CellCollector CANCER01 (DC01) and CellSearch system. CTC counts were analyzed and compared before and after radiotherapy (two sampling time points) in 51 high-risk non-metastatic PCa patients and were further compared according to isolation technique; further, CTC counts were correlated to clinical features. Use of DC01 resulted in a significantly higher percentage of CTC-positive samples compared to CellSearch (33.7% vs. 18.6%;

Identifiants

pubmed: 31277254
pii: cancers11070933
doi: 10.3390/cancers11070933
pmc: PMC6678903
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Austrian Science Fund (FWF)
ID : I 1220-B19
Organisme : Franz Lanyar-Stiftung at the Medical University Graz
ID : #394

Références

Cancer Cell. 2003 Sep;4(3):209-21
pubmed: 14522255
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Cancer Res. 2004 Dec 15;64(24):9209-16
pubmed: 15604294
Oncogene. 2005 May 26;24(23):3847-52
pubmed: 15750627
Urology. 2005 Apr;65(4):713-8
pubmed: 15833514
Science. 2005 Oct 28;310(5748):644-8
pubmed: 16254181
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24
pubmed: 16857794
Cancer Res. 2006 Sep 1;66(17):8337-41
pubmed: 16951139
J Urol. 2007 Feb;177(2):540-5
pubmed: 17222629
Clin Cancer Res. 2007 Feb 1;13(3):920-8
pubmed: 17289886
Clin Cancer Res. 2007 Jul 15;13(14):4105-10
pubmed: 17634536
Urology. 2007 Oct;70(4):630-3
pubmed: 17991527
Clin Cancer Res. 2007 Dec 1;13(23):7053-8
pubmed: 18056182
Cancer Cell. 2008 Jan;13(1):58-68
pubmed: 18167340
J Urol. 2008 Jun;179(6):2187-91; discussion 2191
pubmed: 18423725
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Cancer Res. 2009 Mar 15;69(6):2305-13
pubmed: 19244107
J Clin Oncol. 2009 May 1;27(13):2177-84
pubmed: 19332733
Nat Rev Clin Oncol. 2009 Jun;6(6):339-51
pubmed: 19399023
Ann Oncol. 2010 Apr;21(4):729-33
pubmed: 19850639
Ann Oncol. 2010 May;21(5):1006-12
pubmed: 19861577
J Clin Invest. 2010 Aug;120(8):2715-30
pubmed: 20644256
Ann N Y Acad Sci. 2010 Oct;1210:66-77
pubmed: 20973800
Clin Chem. 2011 Mar;57(3):421-30
pubmed: 21245367
J Cell Biol. 2011 Feb 7;192(3):373-82
pubmed: 21300848
Clin Chem. 2011 Sep;57(9):1242-55
pubmed: 21784769
Int J Oncol. 2012 Oct;41(4):1241-50
pubmed: 22825490
Urology. 2012 Dec;80(6):1328-32
pubmed: 23063057
Sci Transl Med. 2013 Jan 23;5(169):169ra10
pubmed: 23345608
J Cancer Res Clin Oncol. 2013 May;139(5):755-63
pubmed: 23358719
J Endourol. 2013 Aug;27(8):1061-7
pubmed: 23641793
Prostate Cancer Prostatic Dis. 2014 Mar;17(1):57-63
pubmed: 24189998
J Clin Oncol. 2014 Apr 10;32(11):1136-42
pubmed: 24616308
J Natl Cancer Inst. 2014 May 15;106(5):null
pubmed: 24832787
Eur Urol. 2014 Sep;66(3):550-60
pubmed: 24836057
Curr Urol. 2013 Nov;7(2):65-9
pubmed: 24917761
Anticancer Res. 2014 Jul;34(7):3641-6
pubmed: 24982381
J Cancer Res Clin Oncol. 2014 Dec;140(12):2157-62
pubmed: 25028119
Cell Rep. 2014 Aug 7;8(3):798-806
pubmed: 25066126
Nat Rev Cancer. 2014 Sep;14(9):623-31
pubmed: 25154812
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Urol Oncol. 2015 Mar;33(3):110.e1-9
pubmed: 25595577
Nat Methods. 2015 Jul;12(7):685-91
pubmed: 25984697
Nat Genet. 2015 Jul;47(7):736-45
pubmed: 26005866
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):358-64
pubmed: 26238233
Sci Transl Med. 2015 Aug 26;7(302):302ra133
pubmed: 26311728
Anticancer Res. 2015 Oct;35(10):5679-85
pubmed: 26408743
Clin Cancer Res. 2016 May 1;22(9):2197-206
pubmed: 26667488
Mol Oncol. 2016 Mar;10(3):374-94
pubmed: 26897752
Proc Natl Acad Sci U S A. 2016 May 3;113(18):4947-52
pubmed: 27091969
PLoS One. 2016 May 16;11(5):e0155126
pubmed: 27182774
JAMA Oncol. 2016 Nov 1;2(11):1441-1449
pubmed: 27262168
Sci Transl Med. 2016 Jul 6;8(346):346ra92
pubmed: 27384348
Sci Rep. 2016 Dec 21;6:39736
pubmed: 28000772
Sci Rep. 2017 Feb 24;7:43424
pubmed: 28233867
J Clin Oncol. 2017 Jul 1;35(19):2149-2156
pubmed: 28384066
Sci Rep. 2017 May 26;7(1):2433
pubmed: 28550299
Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):56-63
pubmed: 28882555
Adv Clin Chem. 2017;82:71-103
pubmed: 28939214
Clin Chem. 2018 Feb;64(2):297-306
pubmed: 29122836
Clin Chem. 2018 Mar;64(3):536-546
pubmed: 29301749
Oncotarget. 2018 Apr 10;9(27):19283-19293
pubmed: 29721202
J Vis Exp. 2018 May 15;(135):
pubmed: 29863657
Clin Cancer Res. 2018 Nov 15;24(22):5635-5644
pubmed: 30093450
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
Eur Urol. 2019 Mar;75(3):535-536
pubmed: 30466892
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cell. 2019 Jan 10;176(1-2):98-112.e14
pubmed: 30633912
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):33-35
pubmed: 30967237
J Urol. 1995 Aug;154(2 Pt 1):407-13
pubmed: 7541857
Science. 1997 Mar 28;275(5308):1943-7
pubmed: 9072974
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478

Auteurs

Shukun Chen (S)

Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Department of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.

Gerlinde Tauber (G)

Department of Therapeutic Radiology and Oncology, Medical University of Graz, 8036 Graz, Austria.

Tanja Langsenlehner (T)

Department of Therapeutic Radiology and Oncology, Medical University of Graz, 8036 Graz, Austria.

Linda Maria Schmölzer (LM)

Department of Therapeutic Radiology and Oncology, Medical University of Graz, 8036 Graz, Austria.

Michaela Pötscher (M)

Department of Therapeutic Radiology and Oncology, Medical University of Graz, 8036 Graz, Austria.

Sabine Riethdorf (S)

Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Andra Kuske (A)

Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Gerd Leitinger (G)

Department of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.

Karl Kashofer (K)

Diagnostic and Research Institute of Pathology, Medical University Graz, 8036 Graz, Austria.

Zbigniew T Czyż (ZT)

Division Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053 Regensburg, Germany.

Bernhard Polzer (B)

Division Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053 Regensburg, Germany.

Klaus Pantel (K)

Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Peter Sedlmayr (P)

Department of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.

Thomas Kroneis (T)

Department of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria. thomas.kroneis@medunigraz.at.

Amin El-Heliebi (A)

Department of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.
Center for Biomarker Research, CBmed, 8010 Graz, Austria.

Classifications MeSH